These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1199 related items for PubMed ID: 18179782

  • 61. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
    Ghali JK, Zmily HD, Farah JO, Daifallah S.
    IDrugs; 2010 Nov; 13(11):782-92. PubMed ID: 21046526
    [Abstract] [Full Text] [Related]

  • 62. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Eur J Pharmacol; 2008 Feb 26; 581(1-2):121-31. PubMed ID: 18154949
    [Abstract] [Full Text] [Related]

  • 63. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH, Serrano C.
    Int J Cardiol; 2007 Aug 09; 120(1):1-9. PubMed ID: 17346825
    [Abstract] [Full Text] [Related]

  • 64. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide.
    Nishizaki Y, Yamagami S, Sesoko M, Yamashita H, Daida H.
    J Cardiol Cases; 2013 Nov 09; 8(5):151-154. PubMed ID: 30546768
    [Abstract] [Full Text] [Related]

  • 65. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, Fujiki H, Miyazaki S.
    Circ Heart Fail; 2012 Jul 01; 5(4):484-92. PubMed ID: 22628529
    [Abstract] [Full Text] [Related]

  • 66. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
    Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M.
    J Am Coll Cardiol; 2008 Nov 04; 52(19):1540-5. PubMed ID: 19007589
    [Abstract] [Full Text] [Related]

  • 67. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators.
    Cardiovasc Drugs Ther; 2011 Dec 04; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [Abstract] [Full Text] [Related]

  • 68. Sclederma of Poria cocos exerts its diuretic effect via suppression of renal aquaporin-2 expression in rats with chronic heart failure.
    Wu ZL, Ren H, Lai WY, Lin S, Jiang RY, Ye TC, Shen QB, Zeng QC, Xu DL.
    J Ethnopharmacol; 2014 Aug 08; 155(1):563-71. PubMed ID: 24933223
    [Abstract] [Full Text] [Related]

  • 69. Muzolimine in chronic renal failure: a study in 16 patients.
    Stratta P, Dogliani M, Squiccimarro G, Colla L, Vercellone A.
    Z Kardiol; 1985 Aug 08; 74 Suppl 2():125-8. PubMed ID: 4002786
    [Abstract] [Full Text] [Related]

  • 70. Pharmacological properties of the novel highly potent diuretic 7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinone 4-oxime-O-sulfonic acid potassium salt.
    Shinkawa T, Yamasaki F, Kikuchi A, Nakakuki M, Nishijima K, Uemura A, Mizota M, Orita Y.
    Arzneimittelforschung; 1992 Dec 08; 42(12):1466-72. PubMed ID: 1337698
    [Abstract] [Full Text] [Related]

  • 71. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y, Inomata T, Kida K, Shibagaki Y, Sato N, Izumi T, Ako J, Kanagawa Aquaresis Investigators.
    Heart Vessels; 2019 Mar 08; 34(3):442-451. PubMed ID: 30259172
    [Abstract] [Full Text] [Related]

  • 72. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 08; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 73. Solute-free water retention in preascitic cirrhotic rats following intravenous water loading.
    Sansoe G, Aragno M, Smedile A, Rizzetto M, Rosina F.
    J Physiol Pharmacol; 2009 Dec 08; 60(4):111-7. PubMed ID: 20065504
    [Abstract] [Full Text] [Related]

  • 74. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M, Hirawa N, Sumida K, Kagimoto M, Ehara Y, Okuyama Y, Fujita M, Fujiwara A, Kobayashi M, Kobayashi Y, Yamamoto Y, Saka S, Yatsu K, Fujikawa T, Toya Y, Yasuda G, Tamura K, Umemura S.
    Clin Exp Nephrol; 2017 Oct 08; 21(5):858-865. PubMed ID: 28190113
    [Abstract] [Full Text] [Related]

  • 75. Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure.
    Tomiyama H, Nakayama T, Watanabe G, Shiojima K, Sakuma Y, Yamamoto A, Imai Y, Yoshida H, Doba N.
    Am Heart J; 1999 Mar 08; 137(3):543-8. PubMed ID: 10047639
    [Abstract] [Full Text] [Related]

  • 76. V2 receptor antagonism with tolvaptan in heart failure.
    Costello-Boerrigter LC, Boerrigter G, Burnett JC.
    Expert Opin Investig Drugs; 2007 Oct 08; 16(10):1639-47. PubMed ID: 17922627
    [Abstract] [Full Text] [Related]

  • 77. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M, Poo JL, Jiménez W, Bordas N, Leivas A, Morales-Ruiz M, Muñoz RM, Pérez M, Arroyo V, Rivera F, Rodés J.
    J Pharmacol Exp Ther; 1999 Apr 08; 289(1):194-201. PubMed ID: 10087004
    [Abstract] [Full Text] [Related]

  • 78. Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF).
    Miyata M, Sasaki T, Ikeda Y, Shinsato T, Kubozono T, Furusho Y, Kusumoto A, Hamasaki S, Tei C, COLD-CHF Investigators.
    J Cardiol; 2012 May 08; 59(3):352-8. PubMed ID: 22365947
    [Abstract] [Full Text] [Related]

  • 79. In right or biventricular chronic heart failure addition of thiazides to loop diuretics to achieve a sequential blockade of the nephron is associated with increased risk of dilutional hyponatremia: results of a case-control study.
    De Vecchis R, Ariano C, Esposito C, Giasi A, Cioppa C, Cantatrione S.
    Minerva Cardioangiol; 2012 Oct 08; 60(5):517-29. PubMed ID: 23018431
    [Abstract] [Full Text] [Related]

  • 80. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
    Takada T, Masaki T, Hoshiyama A, Toki T, Kamata Y, Shichiri M.
    Nephrology (Carlton); 2018 Sep 08; 23(9):883-886. PubMed ID: 29665203
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.